Gene-Modified Blister Fluid–Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa
Journal of Investigative Dermatology · 2023
DOI: 10.1016/j.jid.2023.05.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2023. Verfasst von Yasushi Kikuchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Gene Therapy Science, Graduate School of Medicine, Osaka University, Suita, Japan; Department of Dermatology, Graduate School…. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Mesenchymal Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Recessive dystrophic epidermolysis bullosa (RDEB) is a genodermatosis caused by variants in COL7A1-encoded type VII collagen, a major component of anchoring fibrils. In this study, we developed an ex vivo gene therapy for RDEB using autologous mesenchymal stromal cells (MSCs). On the basis of our previous studies, we first attempted to isolate MSCs from the blister fluid of patients with RDEB and succeeded in obtaining cells with a set of MSC characteristics from all 10 patients. We termed these cells blister fluid-derived MSCs. Blister fluid-derived MSCs were genetically modified and injected into skins of type VII collagen-deficient neonatal mice transplanted onto immunodeficient mice, resulting in continuous and widespread expression of type VII collagen at the dermal-epidermal junction, particularly when administered into blisters. When injected intradermally, the efforts were not successful. The gene-modified blister fluid-derived MSCs could be cultured as cell sheets and applied to the dermis with an efficacy equivalent to that of intrablister administration. In conclusion, we successfully developed a minimally invasive and highly efficient ex vivo gene therapy for RDEB. This study shows the successful application of gene therapy in the RDEB mouse model for both early blistering skin and advanced ulcerative lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Gene Therapy Science, Graduate School of Medicine, Osaka University, Suita, Japan; Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Japan.
- Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Suita, Japan.
- Basic Research Department, StemRIM, Ibaraki, Japan.
- Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Japan; Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Suita, Japan.
- Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.
- Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Kikuchi, Y., Tamakoshi, T., Ishida, R., Kobayashi, R., Mori, S., Ishida-Yamamoto, A., Fujimoto, M., Kaneda, Y., & Tamai, K. (2023). Gene-Modified Blister Fluid–Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2023.05.021
Vancouver
Kikuchi Y, Tamakoshi T, Ishida R, Kobayashi R, Mori S, Ishida-Yamamoto A, et al. Gene-Modified Blister Fluid–Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology. 2023. doi:10.1016/j.jid.2023.05.021
BibTeX
@article{Kikuchi2023,
author = {Kikuchi, Yasushi and Tamakoshi, Tomoki and Ishida, Ryuichi and Kobayashi, Ryosuke and Mori, Shiho and Ishida-Yamamoto, Akemi and Fujimoto, Manabu and Kaneda, Yasufumi and Tamai, Katsuto},
title = {Gene-Modified Blister Fluid–Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa},
journal = {Journal of Investigative Dermatology},
year = {2023},
doi = {10.1016/j.jid.2023.05.021}
}
EUVIMED